Back to search

Peptide record

TPDB21014

Antibacterial Anticancer Toxicity modified_plain modified
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB21014
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 14-aa modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
HFLGTLVNLAKKIX
Physicochemical Analysis
C69H116N18O16
RDCEQMPSWY
L
1453.79
10.60
3
0
7
+2
0.29
0.650
139.29
Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour
0
0.00
2
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
0
E
0
Q
1
G
1
H
1
I
3
L
2
K
0
M
1
F
0
P
0
S
1
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 3 K: 2 M: 0 F: 1 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 1
Chemical Descriptors
14
C69H116N18O16
1453.79
10.60
+2
0.29
0.650
Evidence Records 3 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
250 µM
Hemolytic Cytotoxic
50% Hemolysis | 250 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa. | Peptides | 2007
Evidence 2 Activity

Activity

50% Cell death
Toxicity
90 µM
Cytotoxic
50% Cell death | 90 | µM | target cell: Mouse fibroblasts L929

Target

Mouse fibroblasts L929

Source & Reference

NA
DBAASP
Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa. | Peptides | 2007
Evidence 3 Activity

Activity

LC50
Toxicity
90 µM
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 50% Hemolysis=130 µM | Cytotoxicity: Mouse fibroblasts L929: LC50=90 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2007 Oct 28(10):2075-80.